Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 160

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 160
---
eningitis, Travel and EndemicsVaccines    |       1,316 | +3.9%            | +5.4%       |          736 | +1.5%       |    204 | +28.7%      |              376 | +3.2%       |
| Biopharma                                  |      41,081 | +8.6%            | +11.3%      |       19,986 | +16.2%      |  9,027 | +2.3%       |           12,068 | +10.7%      |
| Of which new launches (*)                  |       4,535 | +102.7%          | +106.3%     |        2,998 | +97.0%      |    960 | +95.3%      |              577 | +199.1%     |

| 74 | SANOFIFORM 20-F2024 |

| PART I                                               |
| ITEM 5. Operating and Financial Review and Prospects |

3/ Net sales – Biopharma segment In 2024 , net sales for the Biopharma segment (see " — A.1.5. Segment Information and Business net income” for detailed disclosures about our operating segments and Note D.35. to our consolidated financial statements included at Item 18. of this annual report) amounted to € 41,081 million, up 8.6% on a reported basis and 11.3% at CER. The year-on-year reported-basis increase of € 3,264 million reflects adverse exchange rate effects amounting to € 992 million, and the following principal effects at CER: • a solid performance from Dupixent (+€ 2,480 million, a 23.1% increase), ALTUVIIIO (+€ 525 million), and Lantus (+ €295 million); which more than offset a drop in sales of Aubagio (-€ 567 million); and • triple-digit growth for Beyfortus (to € 1,173 million, a 214.4% increase). Comments on the performances of our major Biopharma segment products are provided below. New launches ALTUVIIIO ( hemophilia A) posted sales of € 682 million in 2024 , with 90% generated in the United States. Growth continued to be driven by patient switches from older factor medicines and increasingly, from non-factor